Key clinical point: The presence of nail dystrophy predicted a better treatment response to secukinumab in patients with psoriatic arthritis (PsA) and axial symptoms.

Major finding: Presence vs absence of nail dystrophy was associated with the achievement of significantly better Assessment of SpondyloArthritis International Society 20 response in the 300 mg secukinumab (odds ratio 5.0; 95% CI 1.47-17.19) vs placebo group (interaction alone P  =  .029).

Study details: Findings are from a post hoc analysis of the phase 3b MAXIMISE trial including 473 adult patients with PsA and axial manifestations who were randomly assigned to receive secukinumab (150 or 300 mg) or placebo.

Disclosures: H Marzo-Ortega and LC Coates reported receiving grants from the UK National Institute for Health Research. The other authors reported ties with several sources outside this work.

Source: Baraliakos X et al. Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: A post-hoc analysis of the MAXIMISE trial. RMD Open. 2022;8(2):e002303 (Jul 18). Doi: 10.1136/rmdopen-2022-002303

Key clinical point: The presence of nail dystrophy predicted a better treatment response to secukinumab in patients with psoriatic arthritis (PsA) and axial symptoms.

Major finding: Presence vs absence of nail dystrophy was associated with the achievement of significantly better Assessment of SpondyloArthritis International Society 20 response in the 300 mg secukinumab (odds ratio 5.0; 95% CI 1.47-17.19) vs placebo group (interaction alone P  =  .029).

Study details: Findings are from a post hoc analysis of the phase 3b MAXIMISE trial including 473 adult patients with PsA and axial manifestations who were randomly assigned to receive secukinumab (150 or 300 mg) or placebo.

Disclosures: H Marzo-Ortega and LC Coates reported receiving grants from the UK National Institute for Health Research. The other authors reported ties with several sources outside this work.

Source: Baraliakos X et al. Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: A post-hoc analysis of the MAXIMISE trial. RMD Open. 2022;8(2):e002303 (Jul 18). Doi: 10.1136/rmdopen-2022-002303

Key clinical point: The presence of nail dystrophy predicted a better treatment response to secukinumab in patients with psoriatic arthritis (PsA) and axial symptoms.

Major finding: Presence vs absence of nail dystrophy was associated with the achievement of significantly better Assessment of SpondyloArthritis International Society 20 response in the 300 mg secukinumab (odds ratio 5.0; 95% CI 1.47-17.19) vs placebo group (interaction alone P  =  .029).

Study details: Findings are from a post hoc analysis of the phase 3b MAXIMISE trial including 473 adult patients with PsA and axial manifestations who were randomly assigned to receive secukinumab (150 or 300 mg) or placebo.

Disclosures: H Marzo-Ortega and LC Coates reported receiving grants from the UK National Institute for Health Research. The other authors reported ties with several sources outside this work.

Source: Baraliakos X et al. Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: A post-hoc analysis of the MAXIMISE trial. RMD Open. 2022;8(2):e002303 (Jul 18). Doi: 10.1136/rmdopen-2022-002303

Key clinical point: The presence of dactylitis and nail disease were associated with improved outcomes in patients with early psoriatic arthritis (PsA) who received etanercept or methotrexate.

Major finding: The presence of both dactylitis and nail disease at baseline were significantly associated with the achievement of minimal disease activity (DA; odds ratio [OR] 1.4; P  =  .0457, and OR 1.8; P  =  .0233, respectively), PsA DA Score (PASDAS) of  low DA (OR 1.8; P  =  .0014, and OR 1.8; P  =  .0168, respectively) responses, and greater reductions in PASDAS scores at week 24 (estimate –3.8; P  =  .0155, and estimate –0.7; P  =  .0005, respectively).

Study details: Findings are from a post hoc analysis of the phase 3 SEAM-PsA trial including 851 biologic/methotrexate-naive patients with active PsA who were randomly assigned to receive methotrexate monotherapy, etanercept monotherapy, or methotrexate+etanercept combination therapy.

Disclosures: This study was funded by Immunex, a wholly owned subsidiary of Amgen. Three authors declared being employees or owning stocks in Amgen, and the other authors reported ties with several sources, including Amgen.

Source: Helliwell PS et al. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: Comparison of treatment effects in the SEAM-PsA trial. RMD Open. 2022;8(2):e002366 (Jul 21). Doi: 10.1136/rmdopen-2022-002366

Key clinical point: The presence of dactylitis and nail disease were associated with improved outcomes in patients with early psoriatic arthritis (PsA) who received etanercept or methotrexate.

Major finding: The presence of both dactylitis and nail disease at baseline were significantly associated with the achievement of minimal disease activity (DA; odds ratio [OR] 1.4; P  =  .0457, and OR 1.8; P  =  .0233, respectively), PsA DA Score (PASDAS) of  low DA (OR 1.8; P  =  .0014, and OR 1.8; P  =  .0168, respectively) responses, and greater reductions in PASDAS scores at week 24 (estimate –3.8; P  =  .0155, and estimate –0.7; P  =  .0005, respectively).

Study details: Findings are from a post hoc analysis of the phase 3 SEAM-PsA trial including 851 biologic/methotrexate-naive patients with active PsA who were randomly assigned to receive methotrexate monotherapy, etanercept monotherapy, or methotrexate+etanercept combination therapy.

Disclosures: This study was funded by Immunex, a wholly owned subsidiary of Amgen. Three authors declared being employees or owning stocks in Amgen, and the other authors reported ties with several sources, including Amgen.

Source: Helliwell PS et al. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: Comparison of treatment effects in the SEAM-PsA trial. RMD Open. 2022;8(2):e002366 (Jul 21). Doi: 10.1136/rmdopen-2022-002366

Key clinical point: The presence of dactylitis and nail disease were associated with improved outcomes in patients with early psoriatic arthritis (PsA) who received etanercept or methotrexate.

Major finding: The presence of both dactylitis and nail disease at baseline were significantly associated with the achievement of minimal disease activity (DA; odds ratio [OR] 1.4; P  =  .0457, and OR 1.8; P  =  .0233, respectively), PsA DA Score (PASDAS) of  low DA (OR 1.8; P  =  .0014, and OR 1.8; P  =  .0168, respectively) responses, and greater reductions in PASDAS scores at week 24 (estimate –3.8; P  =  .0155, and estimate –0.7; P  =  .0005, respectively).

Study details: Findings are from a post hoc analysis of the phase 3 SEAM-PsA trial including 851 biologic/methotrexate-naive patients with active PsA who were randomly assigned to receive methotrexate monotherapy, etanercept monotherapy, or methotrexate+etanercept combination therapy.

Disclosures: This study was funded by Immunex, a wholly owned subsidiary of Amgen. Three authors declared being employees or owning stocks in Amgen, and the other authors reported ties with several sources, including Amgen.

Source: Helliwell PS et al. Impact of clinical domains other than arthritis on composite outcomes in psoriatic arthritis: Comparison of treatment effects in the SEAM-PsA trial. RMD Open. 2022;8(2):e002366 (Jul 21). Doi: 10.1136/rmdopen-2022-002366

Key clinical point: Golimumab was effective as a second-line anti-tumor necrosis factor-alpha (TNFα) treatment in a real-world setting of patients with psoriatic arthritis (PsA) who failed the first-line anti-TNFα therapy.

Major finding: After 6 months, 31.9% (95% CI 21.4%–44.0%) and 73.8% (95% CI 58.0%–86.1%) of patients with PsA achieved minimal disease activity and a good/moderate response as per the European Alliance of Associations for Rheumatology, respectively, along with significant improvements in disease activity score in 28 joints based on C-reactive protein score (P < .001).

Study details: Findings are from the prospective, observational, real-world study including 194 patients with moderate-to-active rheumatoid arthritis (n = 39), PsA (n = 91), or axial spondyloarthritis (n = 64) who started golimumab after first-line anti-TNFα inhibitor failure.

Disclosures: This study was funded by MSD Italia S.r.l. Two authors declared being employees of MSD Italia, and the other authors reported ties with several sources, including Merck.

Source: D’Angelo S et al. Effectiveness of golimumab as second anti-TNFα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study. J Clin Med. 2022;11(14):4178 (Jul 19). Doi: 10.3390/jcm11144178

Key clinical point: Golimumab was effective as a second-line anti-tumor necrosis factor-alpha (TNFα) treatment in a real-world setting of patients with psoriatic arthritis (PsA) who failed the first-line anti-TNFα therapy.

Major finding: After 6 months, 31.9% (95% CI 21.4%–44.0%) and 73.8% (95% CI 58.0%–86.1%) of patients with PsA achieved minimal disease activity and a good/moderate response as per the European Alliance of Associations for Rheumatology, respectively, along with significant improvements in disease activity score in 28 joints based on C-reactive protein score (P < .001).

Study details: Findings are from the prospective, observational, real-world study including 194 patients with moderate-to-active rheumatoid arthritis (n = 39), PsA (n = 91), or axial spondyloarthritis (n = 64) who started golimumab after first-line anti-TNFα inhibitor failure.

Disclosures: This study was funded by MSD Italia S.r.l. Two authors declared being employees of MSD Italia, and the other authors reported ties with several sources, including Merck.

Source: D’Angelo S et al. Effectiveness of golimumab as second anti-TNFα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study. J Clin Med. 2022;11(14):4178 (Jul 19). Doi: 10.3390/jcm11144178

Key clinical point: Golimumab was effective as a second-line anti-tumor necrosis factor-alpha (TNFα) treatment in a real-world setting of patients with psoriatic arthritis (PsA) who failed the first-line anti-TNFα therapy.

Major finding: After 6 months, 31.9% (95% CI 21.4%–44.0%) and 73.8% (95% CI 58.0%–86.1%) of patients with PsA achieved minimal disease activity and a good/moderate response as per the European Alliance of Associations for Rheumatology, respectively, along with significant improvements in disease activity score in 28 joints based on C-reactive protein score (P < .001).

Study details: Findings are from the prospective, observational, real-world study including 194 patients with moderate-to-active rheumatoid arthritis (n = 39), PsA (n = 91), or axial spondyloarthritis (n = 64) who started golimumab after first-line anti-TNFα inhibitor failure.

Disclosures: This study was funded by MSD Italia S.r.l. Two authors declared being employees of MSD Italia, and the other authors reported ties with several sources, including Merck.

Source: D’Angelo S et al. Effectiveness of golimumab as second anti-TNFα drug in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis in Italy: GO-BEYOND, a prospective real-world observational study. J Clin Med. 2022;11(14):4178 (Jul 19). Doi: 10.3390/jcm11144178

Key clinical point: The 3-year bimekizumab treatment was well tolerated and effective in reducing the signs and symptoms of psoriatic arthritis (PsA).

Major finding: By week 152, 89.3% of patients had reported ≥1 treatment-emergent adverse event (TEAE), with serious TEAE being reported by 10.7% of patients. At least 20% improvement in American College of Rheumatology score was maintained by 64.1% of patients at week 152 compared with 72.3% of patients at week 48.

Study details: Findings are 3-year results from the phase 2b BE ACTIVE trial including 206 adults with active PsA who were randomly assigned to receive bimekizumab or placebo for 48 weeks, of which 184 patients were enrolled in the open-label extension phase for a further 104 weeks of treatment.

Disclosures: This study was supported by UCB Pharma. Four authors declared being employees of UCB Pharma and shareholders of UCB Pharma or GlaxoSmithKline. The other authors reported ties with various sources.

Source: Coates LC et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 (Jul 13). Doi: 10.1002/art.42280

Key clinical point: The 3-year bimekizumab treatment was well tolerated and effective in reducing the signs and symptoms of psoriatic arthritis (PsA).

Major finding: By week 152, 89.3% of patients had reported ≥1 treatment-emergent adverse event (TEAE), with serious TEAE being reported by 10.7% of patients. At least 20% improvement in American College of Rheumatology score was maintained by 64.1% of patients at week 152 compared with 72.3% of patients at week 48.

Study details: Findings are 3-year results from the phase 2b BE ACTIVE trial including 206 adults with active PsA who were randomly assigned to receive bimekizumab or placebo for 48 weeks, of which 184 patients were enrolled in the open-label extension phase for a further 104 weeks of treatment.

Disclosures: This study was supported by UCB Pharma. Four authors declared being employees of UCB Pharma and shareholders of UCB Pharma or GlaxoSmithKline. The other authors reported ties with various sources.

Source: Coates LC et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 (Jul 13). Doi: 10.1002/art.42280

Key clinical point: The 3-year bimekizumab treatment was well tolerated and effective in reducing the signs and symptoms of psoriatic arthritis (PsA).

Major finding: By week 152, 89.3% of patients had reported ≥1 treatment-emergent adverse event (TEAE), with serious TEAE being reported by 10.7% of patients. At least 20% improvement in American College of Rheumatology score was maintained by 64.1% of patients at week 152 compared with 72.3% of patients at week 48.

Study details: Findings are 3-year results from the phase 2b BE ACTIVE trial including 206 adults with active PsA who were randomly assigned to receive bimekizumab or placebo for 48 weeks, of which 184 patients were enrolled in the open-label extension phase for a further 104 weeks of treatment.

Disclosures: This study was supported by UCB Pharma. Four authors declared being employees of UCB Pharma and shareholders of UCB Pharma or GlaxoSmithKline. The other authors reported ties with various sources.

Source: Coates LC et al. Safety and efficacy of bimekizumab in patients with active psoriatic arthritis: 3-year results from a phase 2b randomized controlled trial and its open-label extension study. Arthritis Rheumatol. 2022 (Jul 13). Doi: 10.1002/art.42280

Key clinical point: RHOA expression level is associated with clinical features, including Union for International Cancer Control (UICC) stage progression and poorly differentiated status, in patients with gastric cancer.

Major finding: High/positive RHOA expression was significantly associated with UICC stage progression (III-IV vs I-II: odds ratio [OR] 1.37; P  =  .02) and poorly differentiated status (poorly differentiated vs well/moderately differentiated: OR,1.65; P  =  .02).

Study details: This was a meta-analysis of 10 retrospective case-control studies including 1389 patients with gastric cancer, of which 735 were RHOA positive and 654 were RHOA negative.

Disclosures: This study was sponsored by the Basic Science Research Program, through the National Research Foundation of Korea, funded by the Ministry of Education, and the Gachon University Gil Medical Center. The authors declared no conflicts of interest.

Source: Nam S et al. RHOA protein expression correlates with clinical features in gastric cancer: A systematic review and meta-analysis. BMC Cancer. 2022; 22(1):798 (Jul 19). Doi: 10.1186/s12885-022-09904-7

Key clinical point: RHOA expression level is associated with clinical features, including Union for International Cancer Control (UICC) stage progression and poorly differentiated status, in patients with gastric cancer.

Major finding: High/positive RHOA expression was significantly associated with UICC stage progression (III-IV vs I-II: odds ratio [OR] 1.37; P  =  .02) and poorly differentiated status (poorly differentiated vs well/moderately differentiated: OR,1.65; P  =  .02).

Study details: This was a meta-analysis of 10 retrospective case-control studies including 1389 patients with gastric cancer, of which 735 were RHOA positive and 654 were RHOA negative.

Disclosures: This study was sponsored by the Basic Science Research Program, through the National Research Foundation of Korea, funded by the Ministry of Education, and the Gachon University Gil Medical Center. The authors declared no conflicts of interest.

Source: Nam S et al. RHOA protein expression correlates with clinical features in gastric cancer: A systematic review and meta-analysis. BMC Cancer. 2022; 22(1):798 (Jul 19). Doi: 10.1186/s12885-022-09904-7

Key clinical point: RHOA expression level is associated with clinical features, including Union for International Cancer Control (UICC) stage progression and poorly differentiated status, in patients with gastric cancer.

Major finding: High/positive RHOA expression was significantly associated with UICC stage progression (III-IV vs I-II: odds ratio [OR] 1.37; P  =  .02) and poorly differentiated status (poorly differentiated vs well/moderately differentiated: OR,1.65; P  =  .02).

Study details: This was a meta-analysis of 10 retrospective case-control studies including 1389 patients with gastric cancer, of which 735 were RHOA positive and 654 were RHOA negative.

Disclosures: This study was sponsored by the Basic Science Research Program, through the National Research Foundation of Korea, funded by the Ministry of Education, and the Gachon University Gil Medical Center. The authors declared no conflicts of interest.

Source: Nam S et al. RHOA protein expression correlates with clinical features in gastric cancer: A systematic review and meta-analysis. BMC Cancer. 2022; 22(1):798 (Jul 19). Doi: 10.1186/s12885-022-09904-7

Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.

Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P  =  .02) and overall survival (OS; aHR 4.55; P  =  .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P  =  .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P  =  .02 and aHR 6.89; P < .01, respectively).

Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.

Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.

Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6

Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.

Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P  =  .02) and overall survival (OS; aHR 4.55; P  =  .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P  =  .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P  =  .02 and aHR 6.89; P < .01, respectively).

Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.

Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.

Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6

Key clinical point: Both initial radiological clinical stage (cStage) and post-neoadjuvant chemotherapy pathological stage (ypStage) are independent factors associated with survival outcomes in patients treated with neoadjuvant chemotherapy for gastric cancer.

Major finding: cStage IIIC vs II was independently associated with a poor progression-free survival (PFS; adjusted hazard ratio [aHR] 3.53; P  =  .02) and overall survival (OS; aHR 4.55; P  =  .02). ypStage II and III vs 0/I were independent factors for poor PFS (aHR 3.11; P  =  .01 and aHR 6.98; P < .01, respectively) and OS (aHR 3.49; P  =  .02 and aHR 6.89; P < .01, respectively).

Study details: This post hoc analysis of the PRODIGY study included 212 patients with gastric cancer who received neoadjuvant chemotherapy followed by surgical resection and adjuvant S-1.

Disclosures: The PRODIGY study was sponsored by Sanofi. Some authors declared serving as consultants for and receiving honoraria from various sources.

Source: Kim HD et al. Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: A sub-analysis of the PRODIGY study. Gastric Cancer. 2022 (Aug 3). Doi: 10.1007/s10120-022-01325-6

Key clinical point: A low baseline albumin level is significantly associated with hyperprogressive disease (HPD) development and worse survival outcomes after programmed cell death-1 (PD-1) blockade in patients with advanced gastric cancer (AGC).

Major finding: The optimal albumin cut-off value for predicting HPD was <3.25 mg/dL, with an area under the receiver operating curve of 0.7708 (P  =  .0022). Patients with albumin levels of <3.25 mg/dL had worse progression-free (hazard ratio [HR] 1.928; 95% CI 1.289-2.885) and overall (HR 1.833; 95% CI 1.211-2.774) survival.

Study details: This retrospective study included 169 patients with AGC who received PD-1 blockade therapy (nivolumab or pembrolizumab; n = 112) or irinotecan monotherapy (n = 57).

Disclosures: This study was funded by the National Research Foundation of Korea by the Korean government, among others. The authors declared no conflicts of interest.

Source: Kim CG et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387-399 (Jul 13). Doi: 10.1016/j.ejca.2022.05.042

Key clinical point: A low baseline albumin level is significantly associated with hyperprogressive disease (HPD) development and worse survival outcomes after programmed cell death-1 (PD-1) blockade in patients with advanced gastric cancer (AGC).

Major finding: The optimal albumin cut-off value for predicting HPD was <3.25 mg/dL, with an area under the receiver operating curve of 0.7708 (P  =  .0022). Patients with albumin levels of <3.25 mg/dL had worse progression-free (hazard ratio [HR] 1.928; 95% CI 1.289-2.885) and overall (HR 1.833; 95% CI 1.211-2.774) survival.

Study details: This retrospective study included 169 patients with AGC who received PD-1 blockade therapy (nivolumab or pembrolizumab; n = 112) or irinotecan monotherapy (n = 57).

Disclosures: This study was funded by the National Research Foundation of Korea by the Korean government, among others. The authors declared no conflicts of interest.

Source: Kim CG et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387-399 (Jul 13). Doi: 10.1016/j.ejca.2022.05.042

Key clinical point: A low baseline albumin level is significantly associated with hyperprogressive disease (HPD) development and worse survival outcomes after programmed cell death-1 (PD-1) blockade in patients with advanced gastric cancer (AGC).

Major finding: The optimal albumin cut-off value for predicting HPD was <3.25 mg/dL, with an area under the receiver operating curve of 0.7708 (P  =  .0022). Patients with albumin levels of <3.25 mg/dL had worse progression-free (hazard ratio [HR] 1.928; 95% CI 1.289-2.885) and overall (HR 1.833; 95% CI 1.211-2.774) survival.

Study details: This retrospective study included 169 patients with AGC who received PD-1 blockade therapy (nivolumab or pembrolizumab; n = 112) or irinotecan monotherapy (n = 57).

Disclosures: This study was funded by the National Research Foundation of Korea by the Korean government, among others. The authors declared no conflicts of interest.

Source: Kim CG et al. Hyperprogressive disease during PD-1 blockade in patients with advanced gastric cancer. Eur J Cancer. 2022;172:387-399 (Jul 13). Doi: 10.1016/j.ejca.2022.05.042

Key clinical point: Despite lower complete resection rates and a higher risk for recurrence, endoscopic resection (ER) offers similar long-term survival outcomes and serious adverse event (AE) rates and shorter hospital stays compared with surgery in early gastric cancer (EGC).

Major finding: The ER vs surgery group had a lower complete resection rate (risk difference [RD] −0.1; P < .00001), shorter length of hospital stay (P < .00001), higher rate of recurrence (RD 0.07; P < .00001), and comparable 5-year overall survival (RD −0.01; P  =  .38), cancer-specific survival (RD 0.01; P < .17), and serious AE rate (RD −0.03; P  =  .13).

Study details: This was a meta-analysis of 29 observational cohort studies (prospective: n = 2; retrospective: n = 27) involving 20,559 patients with EGC who underwent ER (n = 7709) or surgery (n = 12,850).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Bestetti AM et al. endoscopic resection versus surgery in the treatment of early gastric cancer: A systematic review and meta-analysis. Front Oncol. 2022;12:939244 (Jul 12). Doi: 10.3389/fonc.2022.939244

Key clinical point: Despite lower complete resection rates and a higher risk for recurrence, endoscopic resection (ER) offers similar long-term survival outcomes and serious adverse event (AE) rates and shorter hospital stays compared with surgery in early gastric cancer (EGC).

Major finding: The ER vs surgery group had a lower complete resection rate (risk difference [RD] −0.1; P < .00001), shorter length of hospital stay (P < .00001), higher rate of recurrence (RD 0.07; P < .00001), and comparable 5-year overall survival (RD −0.01; P  =  .38), cancer-specific survival (RD 0.01; P < .17), and serious AE rate (RD −0.03; P  =  .13).

Study details: This was a meta-analysis of 29 observational cohort studies (prospective: n = 2; retrospective: n = 27) involving 20,559 patients with EGC who underwent ER (n = 7709) or surgery (n = 12,850).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Bestetti AM et al. endoscopic resection versus surgery in the treatment of early gastric cancer: A systematic review and meta-analysis. Front Oncol. 2022;12:939244 (Jul 12). Doi: 10.3389/fonc.2022.939244

Key clinical point: Despite lower complete resection rates and a higher risk for recurrence, endoscopic resection (ER) offers similar long-term survival outcomes and serious adverse event (AE) rates and shorter hospital stays compared with surgery in early gastric cancer (EGC).

Major finding: The ER vs surgery group had a lower complete resection rate (risk difference [RD] −0.1; P < .00001), shorter length of hospital stay (P < .00001), higher rate of recurrence (RD 0.07; P < .00001), and comparable 5-year overall survival (RD −0.01; P  =  .38), cancer-specific survival (RD 0.01; P < .17), and serious AE rate (RD −0.03; P  =  .13).

Study details: This was a meta-analysis of 29 observational cohort studies (prospective: n = 2; retrospective: n = 27) involving 20,559 patients with EGC who underwent ER (n = 7709) or surgery (n = 12,850).

Disclosures: No source of funding was reported. The authors declared no conflicts of interest.

Source: Bestetti AM et al. endoscopic resection versus surgery in the treatment of early gastric cancer: A systematic review and meta-analysis. Front Oncol. 2022;12:939244 (Jul 12). Doi: 10.3389/fonc.2022.939244

Key clinical point: Preoperative plasma levels of the appetite-regulating gut hormone ghrelin may predict postoperative weight loss in patients who have undergone subtotal gastrectomy (STG) for gastric cancer.

Major finding: After adjusting for confounders, the area under the curve preoperative ghrelin level showed a significant negative correlation (ρ –0.8; P  =  .024) with the change in weight loss in the 4 months after STG.

Study details: Findings are from a prospective study including 13 patients aged 20-75 years with gastric cancer who underwent STG and 14 controls with no history of gastrointestinal surgery.

Disclosures: This study was supported by The Korean Society of Neurogastroenterology and Motility. The authors declared no conflicts of interest.

Source: Jung HK et al. Association between gut regulatory hormones and post-operative weight loss following gastrectomy in patients with gastric cancer. J Neurogastroenterol Motil. 2022;28(3):409-417 (Jul 30). Doi: 10.5056/jnm21145

Key clinical point: Preoperative plasma levels of the appetite-regulating gut hormone ghrelin may predict postoperative weight loss in patients who have undergone subtotal gastrectomy (STG) for gastric cancer.

Major finding: After adjusting for confounders, the area under the curve preoperative ghrelin level showed a significant negative correlation (ρ –0.8; P  =  .024) with the change in weight loss in the 4 months after STG.

Study details: Findings are from a prospective study including 13 patients aged 20-75 years with gastric cancer who underwent STG and 14 controls with no history of gastrointestinal surgery.

Disclosures: This study was supported by The Korean Society of Neurogastroenterology and Motility. The authors declared no conflicts of interest.

Source: Jung HK et al. Association between gut regulatory hormones and post-operative weight loss following gastrectomy in patients with gastric cancer. J Neurogastroenterol Motil. 2022;28(3):409-417 (Jul 30). Doi: 10.5056/jnm21145

Key clinical point: Preoperative plasma levels of the appetite-regulating gut hormone ghrelin may predict postoperative weight loss in patients who have undergone subtotal gastrectomy (STG) for gastric cancer.

Major finding: After adjusting for confounders, the area under the curve preoperative ghrelin level showed a significant negative correlation (ρ –0.8; P  =  .024) with the change in weight loss in the 4 months after STG.

Study details: Findings are from a prospective study including 13 patients aged 20-75 years with gastric cancer who underwent STG and 14 controls with no history of gastrointestinal surgery.

Disclosures: This study was supported by The Korean Society of Neurogastroenterology and Motility. The authors declared no conflicts of interest.

Source: Jung HK et al. Association between gut regulatory hormones and post-operative weight loss following gastrectomy in patients with gastric cancer. J Neurogastroenterol Motil. 2022;28(3):409-417 (Jul 30). Doi: 10.5056/jnm21145

Key clinical point: Computed tomography-determined low skeletal muscle mass (SMM) predicts worse overall survival (OS) in patients with gastric cancer and associated cachexia but not in those without cachexia.

Major finding: Patients with a low vs normal SMM had a significantly worse OS (P  =  .007). A low SMM significantly predicted worse OS in patients with cachexia (P  =  .009) but not in those without cachexia (P  =  .31).

Study details: This retrospective study included 255 adult patients with gastric cancer, of which 117 had low SMM including 49 patients with cachexia.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Wan Q et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2022 (Jul 18). Doi: 10.1002/cam4.5040

Key clinical point: Computed tomography-determined low skeletal muscle mass (SMM) predicts worse overall survival (OS) in patients with gastric cancer and associated cachexia but not in those without cachexia.

Major finding: Patients with a low vs normal SMM had a significantly worse OS (P  =  .007). A low SMM significantly predicted worse OS in patients with cachexia (P  =  .009) but not in those without cachexia (P  =  .31).

Study details: This retrospective study included 255 adult patients with gastric cancer, of which 117 had low SMM including 49 patients with cachexia.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Wan Q et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2022 (Jul 18). Doi: 10.1002/cam4.5040

Key clinical point: Computed tomography-determined low skeletal muscle mass (SMM) predicts worse overall survival (OS) in patients with gastric cancer and associated cachexia but not in those without cachexia.

Major finding: Patients with a low vs normal SMM had a significantly worse OS (P  =  .007). A low SMM significantly predicted worse OS in patients with cachexia (P  =  .009) but not in those without cachexia (P  =  .31).

Study details: This retrospective study included 255 adult patients with gastric cancer, of which 117 had low SMM including 49 patients with cachexia.

Disclosures: This study received no specific funding. The authors declared no conflicts of interest.

Source: Wan Q et al. CT-determined low skeletal muscle mass predicts worse overall survival of gastric cancer in patients with cachexia. Cancer Med. 2022 (Jul 18). Doi: 10.1002/cam4.5040